Literature DB >> 25220020

Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking.

Dayong Lee1, Ryan Vandrey2, Damodara R Mendu1, Jeannie A Murray2, Allan J Barnes1, Marilyn A Huestis1.   

Abstract

Oral fluid (OF) offers a simple, non-invasive, directly observable sample collection for clinical and forensic drug testing. Given that chronic cannabis smokers often engage in drug administration multiple times daily, evaluating OF cannabinoid pharmacokinetics during ad libitum smoking is important for practical development of analytical methods and informed interpretation of test results. Eleven cannabis smokers resided in a closed research unit for 51 days, and underwent four, 5-day oral delta-9-tetrahydrocannabinol (THC) treatments. Each medication period was separated by 9 days of ad libitum cannabis smoking from 12:00 to 23:00 h daily. Ten OF samples were collected from 9:00-22:00 h on each of the last ad libitum smoking days (Study Days 4, 18, 32, and 46). As the number of cannabis cigarettes smoked increased over the study days, OF THC, cannabinol (CBN), and 11-nor-9-carboxy-THC (THCCOOH) also increased with a significant effect of time since last smoking (Δtime; range, 0.0-17.4 h) and ≥88% detection rates; concentrations on Day 4 were significantly lower than those on Days 32 and 46 but not Day 18. Within 30 min of smoking, median THC, CBN, and THCCOOH concentrations were 689 µg/L, 116 µg/L, and 147 ng/L, respectively, decreasing to 19.4 µg/L, 2.4 µg/L, and 87.6 ng/L after 10 h. Cannabidiol and 11-hydroxy-THC showed overall lower detection rates of 29 and 8.6%, respectively. Cannabinoid disposition in OF was highly influenced by Δtime and composition of smoked cannabis. Furthermore, cannabinoid OF concentrations increased over ad libitum smoking days, in parallel with increased cannabis self-administration, possibly reflecting development of increased cannabis tolerance.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cannabinoid; cannabis; delta-9-tetrahydrocannabinol; oral fluid

Mesh:

Substances:

Year:  2014        PMID: 25220020      PMCID: PMC4362971          DOI: 10.1002/dta.1718

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  34 in total

1.  Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis.

Authors:  Garry Milman; David M Schwope; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chim Acta       Date:  2012-01-20       Impact factor: 3.786

2.  Subacute effects of heavy marihuana smoking on pulmonary function in healthy men.

Authors:  D P Tashkin; B J Shapiro; Y E Lee; C E Harper
Journal:  N Engl J Med       Date:  1976-01-15       Impact factor: 91.245

3.  Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers.

Authors:  Sebastien Anizan; Garry Milman; Nathalie Desrosiers; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-08-17       Impact factor: 4.142

4.  Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis.

Authors:  Marilyn A Huestis; Edward J Cone
Journal:  J Anal Toxicol       Date:  2004-09       Impact factor: 3.367

5.  Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid.

Authors:  Gerold F Kauert; Johannes G Ramaekers; Erhard Schneider; Manfred R Moeller; Stefan W Toennes
Journal:  J Anal Toxicol       Date:  2007-06       Impact factor: 3.367

6.  Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry.

Authors:  Garry Milman; Allan J Barnes; Ross H Lowe; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2010-01-04       Impact factor: 4.759

7.  Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers.

Authors:  Matthew N Newmeyer; Nathalie A Desrosiers; Dayong Lee; Damodara R Mendu; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2014-03-20       Impact factor: 3.345

8.  The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users.

Authors:  Ryan Vandrey; Maxine L Stitzer; Miriam Z Mintzer; Marilyn A Huestis; Jeannie A Murray; Dayong Lee
Journal:  Drug Alcohol Depend       Date:  2012-08-22       Impact factor: 4.492

9.  Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.

Authors:  Garry Milman; Mateus M Bergamaschi; Dayong Lee; Damodara R Mendu; Allan J Barnes; Ryan Vandrey; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2014-04       Impact factor: 3.681

10.  Detection of conjugated 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid.

Authors:  Christine Moore; Sumandeep Rana; Cynthia Coulter; David Day; Michael Vincent; James Soares
Journal:  J Anal Toxicol       Date:  2007-05       Impact factor: 3.367

View more
  4 in total

Review 1.  The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.

Authors:  Christina A Brezing; Frances R Levin
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

2.  Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration.

Authors:  Madeleine J Swortwood; Matthew N Newmeyer; Maria Andersson; Osama A Abulseoud; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2016-10-13       Impact factor: 3.345

3.  Long-term stability of cannabinoids in oral fluid after controlled cannabis administration.

Authors:  Karl B Scheidweiler; Maria Andersson; Madeleine J Swortwood; Cristina Sempio; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2016-09-13       Impact factor: 3.345

4.  Detection of Δ9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices.

Authors:  Thomas R Arkell; Richard C Kevin; Jordyn Stuart; Nicholas Lintzeris; Paul S Haber; Johannes G Ramaekers; Iain S McGregor
Journal:  Drug Test Anal       Date:  2019-09-10       Impact factor: 3.345

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.